A risk-benefit assessment of interleukin-2 as an adjunct to antiviral therapy in HIV infection

Drug Safety

Volumn 22, Issue 1, 2000, Pages 19-31

  Piscitelli, Stephen C ^a,b   Bhat, Niranjan ^a   Pau, Alice ^a  

^a NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

^b NATIONAL INSTITUTES OF HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIHISTAMINIC AGENT; ANTIRETROVIRUS AGENT; ATROPINE PLUS DIPHENOXYLATE; CD4 ANTIGEN; CODEINE PHOSPHATE; CYTOKINE; DIPHENHYDRAMINE; DROPERIDOL; GRANISETRON; IBUPROFEN; LEVOTHYROXINE; LOPERAMIDE; LORAZEPAM; MORPHINE; ONDANSETRON; OPIATE; PARACETAMOL; PETHIDINE; PROCHLORPERAZINE; PROMETHAZINE; RECOMBINANT INTERLEUKIN 2; TEMAZEPAM; ZOLPIDEM;

ANXIETY NEUROSIS; ARTHRALGIA; CAPILLARY LEAK SYNDROME; CARDIOMYOPATHY; CELL COUNT; CHILL; CLINICAL TRIAL; CONGESTIVE HEART FAILURE; DEPRESSION; DIARRHEA; DRUG SAFETY; ERYTHEMA; FATIGUE; FEVER; HEADACHE; HEART MUSCLE ISCHEMIA; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPOTENSION; HYPOTHYROIDISM; IMMUNOSTIMULATION; INSOMNIA; LUNG EDEMA; MYALGIA; NAUSEA; NOSE CONGESTION; PRIORITY JOURNAL; REVIEW; RISK BENEFIT ANALYSIS; SKIN DISEASE; UREMIA; VERTIGO; VIRUS LOAD; VOMITING;

EID: 0033965995     PISSN: 01145916     EISSN: None     Source Type: Journal    
DOI: 10.2165/00002018-200022010-00003     Document Type: Review

References (58)

1. 1. Palella Jr FJ, Delaney KM, Moorman AC, et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection: HIV Outpatient Study Investigators. N Engl J Med 1998 Mar 26; 338: 853-60
2. 2. Rook AH, Hooks JJ, Quinnan GV, et al. Interleukin-2 enhances the natural killer cell activity of acquired immunodeficiency syndrome patients through a γ-interferon-dependent mechanism. J Immunol 1985; 134: 1503-7
3. 3. Rook AH, Masur H, Lane HC, et al. Interleukin-2 enhances the depressed natural killer and cytomegalovirus-specific cytotoxic activities of lymphocytes from patients with the acquired immunodeficiency syndrome. J Clin Invest 1983; 72: 398-403
4. 4. Winkelstein A, Kingsley LA, Klein RS, et al. Defective T-cell colony formation and IL-2 receptor expression at all stages of HIV infection. Clin Exp Immunol 1988; 71: 417-22
5. 5. Smith K. Interleukin-2: inception, impact and implications. Science 1988; 240: 1169-76
6. 6. Connors M, Kovacs JA, Krevat S, et al. HIV infection induces changes in CD4+ T-cell phenotype within the CD4+ cell repertoire that are not immediately restored by antiviral or immune-based therapies. Nat Med 1997; 3: 533-40
7. 7. Kovacs JA, Vogel S, Albert JM, et al. Controlled trial of interleukin-2 infusions in patients with the human immunodeficiency virus. N Engl J Med 1996; 335: 1350-6
8. 8. Saravolatz L, Mitsuyasu R, Sneller M, et al. Duration of proleukin IL-2 therapy is more important than total dose in achieving CD4 expansion [abstract 1149]. Abstracts of the 36th Interscience Conference on Antimicrobial Agents and Chemotherapy; 1996 Sep 15-18; New Orleans (LA)
9. 9. Carr A, Emery S, Lloyd A, et al. Outpatient continuous intravenous interleukin-2 or subcutaneous, polyethylene glycol-modified interleukin-2 in human immunodeficiency virus-infected patients: a randomized, controlled, multicenter study. J Infect Dis 1998; 178: 992-9
10. 10. Davey Jr RT, Chaitt DG, Piscitelli SC, et al. Subcutaneous administration of interleukin-2 in human immunodeficiency virus type 1-infected persons. J Infect Dis 1997; 175: 781-9
11. 11. Hengge UR, Exner V, Esser S, et al. Randomized controlled phase II trial of subcutaneous interleukin-2 in HIV patients [abstract 612]. Abstracts of the 5th Conference on Retroviruses and Opportunistic Infections; 1998 Feb 1-5; Chicago (IL)
12. 12. Levy Y, Capitant C, Houhou S, et al. IL-2 in HIV patients: a randomized trial comparing SC, PEG, CIV IL-2 with AZT + ddI. Abstracts of the 12th World AIDS Conference; 1998 Jun 28-Jul 3; Geneva, Switzerland
13. 13. Arno A, Ruiz L, Juan M, et al. Efficacy of low-dose subcutaneous interleukin-2 to treat advanced human immunodeficiency versus type 1 in persons with ≥250/ml CD4 T cells and undetectable plasma virus load. J Infect Dis 1999; 180: 56-60
14. 14. Wood LV, Wiggington JM, Zuckerman J, et al. Pharmacokinetics, tolerance, and immunomodulatory activity of recombinant IL-2 in HIV-infected children and adolescents: results of a pilot study [abstract 222]. Abstracts of the 5th Conference on Retroviruses and Opportunistic Infections; 1998 Feb 1-5; Chicago (IL)
15. 15. Davey RT, Chaitt DG, Alberet JM, et al. A randomized trial of high-versus low-dose subcutaneous interleukin-2 outpatient therapy for early human immunodeficiency virus type 1 infection. J Infect Dis 1999; 179: 849-58
16. 16. Davey RT, Murphy R, Graziano F, et al. A randomized, controlled multicenter trial of subcutaneous interleukin-2 therapy in HIV infected patients with CD4 counts 200-500 cells/μI [abstract 357]. Abstracts of the 6th Conference on Retroviruses and Opportunistic Infections; 1999 Jan 31-Feb 4; Chicago (IL)
17. 3 [abstract 354]. Abstracts of the 6th Conference on Retroviruses and Opportunistic Infections; 1999 Jan 31-Feb 4; Chicago (IL)
18. 3 [abstract 355]. Abstracts of the 6th Conference on Retroviruses and Opportunistic Infections; 1999 Jan 31-Feb 4; Chicago (IL)
19. 19. Emery S, Capra W, Vig P, et al. IL-2 therapy for HIV disease: a meta-analysis of three randomized, controlled trials [abstract 608]. Abstracts of the 5th Conference on Retroviruses and Opportunistic Infections. 1998 Feb 1-5; Chicago (IL)
20. 20. Kovacs JA, Baseler M, Dewar RJ, et al. Increases in CD4 T lymphocytes with intermittent courses of interleukin-2 in patients with human immunodeficiency virus infection - a preliminary study. N Engl J Med 1995; 332: 567-75
21. 21. Piscitelli SC, Wells MJ, Metcalf JA, et al. Pharmacokinetics and pharmacodynamics of subcutaneous interleukin-2 in HIV-infected patients. Pharmacotherapy 1996; 16: 754-9
22. 22. Smith KA. Rational interleukin-2 therapy. Cancer J Sci Am 1997; 3 Suppl. 1: S137-40
23. 23. Mier JW, Vachino G, van der Meer JW, et al. Induction of circulating tumor necrosis factor (TNF alpha) as the mechanism for the febrile response to interleukin-2 (IL-2) in cancer patients. J Clin Immunol 1988 Nov; 8 (6): 426-36
24. 24. Mier JW, Vachino G, Klempner MS, et al. Inhibition of interleukin-2-induced tumor necrosis factor release by dexamethasone: prevention of an acquired neutrophil chemotaxis defect and differential suppression of interleukin-2-associated side effects [see comments]. Blood 1990; 76 (10): 1933-40
25. 25. Caligiuri MA. Low-dose recombinant interleukin-2 therapy: rationale and potential clinical applications. Semin Oncol 1993; 20 (6 Suppl. 9): 3-10
26. 26. Smith KA. Lowest dose interleukin-2 immunotherapy [see comments]. Blood 1993; 81 (6): 1414-23
27. 27. Robb RJ, Munck A, Smith KA. T cell growth factor receptor: quantitation, specificity, and biological relevance. J Exp Med 1981; 154 (5): 1455-74
28. 28. Smith KA. The interleukin-2 receptor. Annu Rev Cell Biol 1989; 5: 397-45
29. 29. Teppler H, Kaplan G, Smith KA, et al. Efficacy of low doses of polyethylene glycol derivative of interleukin-2 in modulating the immune response of patents with human immunodeficiency virus type 1 infection. J Infect Dis 1993; 167: 291-8
30. 30. Teppler H, Kaplan G, Smith KA, et al. Prolonged immunostimulatory effect of low-dose polyethylene glycol interleukin-2 in patients with human immunodeficiency virus type 1 infection. J Exp Med 1993; 177: 483-92
31. 31. Wood R, Montoya JG, Kundu SK, et al. Safety and efficacy of polyethylene glycol-modified interleukin-2 and zidovudine in human immunodeficiency virus type 1 infection: a phase I/II study. J Infect Dis 1993; 167: 519-25
32. 32. Jacobson EL, Pilaro F, Smith KA. Rational interleukin-2 therapy for HIV positive individuals: daily low doses enhance immune function without toxicity. Proc Natl Acad Sci U S A 1996; 93: 10405-10
33. 33. Bernstein ZP, Porter MM, Gould M, et al. Prolonged administration of low-dose interleukin-2 in human immunodeficiency virus-associated malignancy results in selective expansion of innate immune effectors without significant clinical toxicity. Blood 1995; 86 (9): 3287-94
34. 34. Bernstein ZP, Barresi G, Gould M, et al. A phase II study of daily subcutaneous low dose interleukin-2 in HIV-associated malignancies [abstract]. J Acquir Immune Defic Syndr Hum Retrovirol 1997; 14: A40
35. 35. Welsh RM. Regulation of virus infections by natural killer cells: a review. Nat Immune Cell Growth Regul 1986; 5 (4): 169-99
36. 36. Caligiuri MA, Murray C, Robertson MJ, et al. Selective modulation of human natural killer cells in vivo after prolonged infusion of low dose recombinant interleukin-2. J Clin Invest 1993; 91: 123-32
37. 37. Aukrust P, Liabakk N-B, Muller F, et al. Serum levels of tumor necrosis factor-α and soluble TNF receptors in human immunodeficiency virus type 1 infection - correlations to clinical, immunologic, and virologic parameters. J Infect Dis 1994; 169: 420-4
38. 38. Wong JK, Hezareh M, Gunthard HF, et al. Recovery of replication-competent HIV despite prolonged suppression of plasma viremia. Science 1997; 278 (5341): 1291-4
39. 39. Finzi D, Hermankova M, Pierson T, et al. Identification of a reservoir for HIV-1 in patients on highly active antiretroviral therapy. Science 1997; 278 (5341): 1295-300
40. 40. Chun TW, Stuyver L, Mizell SB, et al. Presence of an inducible HIV-1 latent reservoir during highly active antiretroviral therapy. Proc Natl Acad Sci U S A 1997; 94 (24): 13193-7
41. 41. Chun TW, Engel D, Berrey MM, et al. Early establishment of a pool of latently infected, resting CD4+ T cells during primary HIV-1 infection. Proc Natl Acad Sci U S A 1998; 95 (15): 8869-73
42. 42. Schrager LK, D'Souza MP. Cellular and anatomical reservoirs of HIV-1 in patients receiving potent antiretroviral combination therapy. JAMA 1998; 280 (1): 67-71
43. 43. Chun TW, Engel D, Mizell SB, et al. Induction of HIV-1 replication in latently infected CD4+ T cells using a combination of cytokines. J Exp Med 1998; 188: 83-91
44. 44. Weidmann E, Bergmann L, Stock J, et al. Rapid cytokine release in cancer patients treated with interleukin-2. J Immunother 1992; 12: 123-31
45. 45. McIntyre CA, Chapman K, Reeder S et al. Treatment of malignant melanoma and renal cell carcinoma with recombinant human interleukin-2: analysis of cytokine levels in sera and culture supernatants. Eur J Cancer 1992; 28: 58-63
46. 46. Schaafsma MR, Falkenburg JH, Landegent JE et al. In vivo production of interleukin-5, granulocyte-monocyte colony-stimulating factor, monocyte colony-stimulating factor, and interleukin-6 during intravenous administration of high-dose interleukin-2 in cancer patients [see comments]. Blood 1991; 78: 1981-7
47. 47. Chun TW, Engel D, Mizell S, et al. Effect of interleukin-2 in diminution of a pool of latently infected, resting CD4+ T cells in HIV-1 infected patients receiving highly active antiretroviral therapy [abstract no. 496]. Abstracts of the 6th Conference on Retroviruses and Opportunistic Infections; 1999 Jan 31-Feb 4; Chicago (IL)
48. 48. Natarajan V, Bosche M, Metcalf JA, et al. HIV-1 replication in patients with undetectable plasma virus receiving HAART. Lancet 1999; 353: 119-20
49. 49. Siegel JP, Puri RK. Interleukin-2 toxicity. J Clin Oncol 1991; 9: 694-704
50. 50. Witzke O, Winterhagen T, Reinhardt W, et al. Comparison between subcutaneous and intravenous interleukin-2 treatment in HIV disease. J Int Med 1998; 244: 235-40
51. 51. Simonelli C, Zannusi S, Sandri S, et al. Concomitant therapy with subcutaneous interleukin-2 and zidovudine plus didanosine in patients with early stage HIV infection. J Acquir Immune Defic Syndr Hum Retrovirol 1999; 20: 20-7
52. 52. Grady C, Anderson, R, Chase GA. Fatigue in HIV-infected men receiving investigational interleukin-2. Nurs Res 1998; 47: 227-34
53. 53. Sundin DJ, Wolin MJ. Toxicity management in patients receiving low-dose aldesleukin therapy. Ann Pharmacol 1998; 32: 1344-52
54. 54. Sumida S, Miller K, Vogel S, et al. Hypothyroidism is associated with IL-2 therapy in a randomized controlled trial (RCT) of IL-2 for the treatment of HIV-infection. Abstracts of the 36th Annual Meeting of the Infectious Diseases Society of America; 1988 Nov 12-15; Denver (CO)
55. 55. Proleukin™ [package insert]. Emeryville, CA: Chiron Therapeutics, 1998
56. 56. Gabriel CM, Minor JR, Vogel S, et al. Supportive care during aldesleukin therapy for patients infected with human immunodeficiency virus. Am J Health Syst Pharm 1997; 54: 1191-3
57. 57. Davey RT, Chaitt RG, Kovacs JA, et al. Long-term follow-up of an early HIV-infected cohort receiving intermittent outpatient treatment with subcutaneous interleukin-2. Abstracts of the 12th World AIDS Conference; 1998 Jun 28-Jul 3; Geneva, Switzerland
58. 58. Walker RE, Hahn B, Kelly GG, et al. Effects of TNF-alpha antagonists thalidomide and monoclonal anti-TNF antibody (cA2) on reducing IL-2-associated toxicities: a randomized, controlled trial [abstract no. 36]. Abstracts of the 4th Conference on Retrovirus and Opportunistic Infections; 1997 Jan 22-26; Washington DC